The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/IIa study to assess the safety, tolerability, PK, and PD of T3011, a genetically modified oncolytic virus (OVs) administered intravenously (IV) in patients with advanced solid tumors.
 
Ziming Li
Speakers' Bureau - Astrazeneca; Pfizer; Roche
 
Jian Zhang
No Relationships to Disclose
 
Shuang Zhang
No Relationships to Disclose
 
Li Zheng
No Relationships to Disclose
 
Zhiye Zhang
No Relationships to Disclose
 
Junbin Wang
No Relationships to Disclose
 
Ying Hu
No Relationships to Disclose
 
Su-xia Luo
Consulting or Advisory Role - KYM Biosciences
 
Weijia Pang
Employment - AstraZeneca; Immvira; MSD
 
Wenmin Fu
Employment - Immvira
 
Yanmei Qin
Employment - Immvira
 
Shun Lu
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; GenomiCare; Hutchison MediPharma; InventisBio Co. Ltd; Menarini; Pfizer; Roche; Simcere; Yuhan; Zai Lab
Speakers' Bureau - AstraZeneca; Hansoh Pharma; Hengrui Therapeutics; Roche
Research Funding - AstraZeneca (Inst); BeiGene (Inst); BMS (Inst); Hansoh (Inst); Hengrui Therapeutics (Inst); Hutchison MediPharma (Inst); Lilly Suzhou Pharmaceutical Co. (Inst); Roche (Inst)